Clinical Trial

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-23; most recent amendment 2025-12-19.
Status change: Not Yet Recruiting → Recruiting 2023-10-05
Trial Details
NCT Number NCT05789303
Lead Sponsor University of Chicago
Collaborators: GlaxoSmithKline, Amgen
Conditions Multiple Myeloma, Relapse Multiple Myeloma
Enrollment 83 participants
Start Date 2023-05-30
Primary Completion 2028-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-22